Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories

Takeda recently announced that the International Society for Pharmaceutical Engineering (ISPE) awarded the company the highest honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA).

In the Supply Chain category, Takeda was recognized for implementing a new patient-centric supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine manufacturing facility in Singen, Germany won the award in the Pharma 4.0 category.

“Our approach to manufacturing is driven by our unwavering commitment to meeting patient needs. These awards further reinforce that mission and showcase the innovation that takes place in our state-of-the-art facilities to develop and deliver breakthrough treatments,” said Thomas Wozniewski, Global Head of Manufacturing and Sourcing, Takeda.

“We are proud to be recognized by ISPE in two FOYA categories and look forward to continuing our digital transformation. »

FOYA Supply Chain recognizes the innovative application of management principles, systems and tools to improve operational speed, robustness and responsiveness. This award recognizes Takeda’s work to completely redesign the supply chain management program for Takeda’s first allogeneic mesenchymal stem cell therapy, whose time from final product to patient administration was unmatched. is only 72 hours.

Due to the short shelf life of allogeneic mesenchymal stem cell therapy and the need for seamless cold chain transport, speed is critical.

Takeda has introduced a cloud-based control tower platform to connect its ecosystem (hospitals, transportation companies, factories, business units) for a “build-to-order” process. The platform allows hospitals to book a manufacturing slot directly through a web portal, then track the delivery status of the final product with end-to-end visibility and alerts at every stage of the supply chain .

In the Pharma 4.0 category, ISPE recognizes facilities that demonstrate how innovation in advanced digital technologies leads to better outcomes in terms of safety, product quality and productivity in a pharmaceutical manufacturing plant.

Takeda’s vaccine facility in Singen, Germany was built with state-of-the-art processing equipment and layered with advanced digital technologies in key areas.

Additionally, Takeda has a sponsored research collaboration with the School of Engineering at the Massachusetts Institute of Technology (MIT) to develop the application to increase inspection accuracy and reduce low false reject rates during operations. routine.

Comments are closed.